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HIV/AIDS has placed significant strain on public health 
institutions in sub-Saharan Africa.1  Simultaneously, severe staff 
shortages, brain drain and increases in health worker illness 
are being experienced in the region.2   
   The South African public health service faces the challenge 
of scaling up the provision of highly active antiretroviral 
therapy (HAART).  It is projected that nearly 1 500 000 patients 
nationally, and nearly 500 000 patients in KwaZulu-Natal 
(KZN), will be on HAART by 2008/2009.  The rollout of a 
national AIDS treatment plan will require over 13 000 posts to 
be created by 2008.3  This is occurring in an environment where 
there are already widespread shortages of medical staff (31% 
of health professional posts were vacant in 2003).4  In addition, 
HIV seroprevalence among health care workers is estimated at 
16%.5  The shortage of health care workers could threaten the 
success of the antiretroviral (ARV) rollout and limit the health 
service’s capacity to respond to HIV/AIDS.
   A study6 conducted at a KZN hospital has shown that it 
is feasible to provide HAART to health care workers.  The 
provision of free HAART to HIV-infected health professionals 
should be introduced or strengthened as a matter of urgency.  
In southern Africa, this strategy could be used to alleviate staff 
shortages and to speed up the rollout of HAART.  Indeed, 
targeted provision of HAART to health care workers may be 
unavoidable if HAART scale-up plans in southern Africa are 
to be achieved.2,5  In countries yet to implement HAART, this 
strategy could be an important starting point in the rollout.6
   This study aims to provide a comprehensive costing of 
HAART to health care workers, which goes beyond the 
estimation of drug and testing costs.  Knowledge of the cost 
of this strategy is vital for planning purposes if it is to be 
adopted as health policy.  This study adds to the scarce body 
of knowledge on the cost of providing HAART in resource-
constrained settings. 
Background
Data were used from two hospitals in Durban, KZN, that 
provide HAART to HIV-infected employees.  Hospital A (to 
preserve confidentiality actual hospital names are not used) 
is a state-subsidised, urban hospital which began offering 
HAART to staff members in September 2001.  HIV counselling, 
testing and management, including provision of HAART, are 
integrated into the general practice service offered to staff.  
   Hospital B is a state-subsidised, peri-urban hospital which 
began providing HAART in March 2003.  Full-time hospital 
staff are given preferential access to the programme.  The staff 
clinic and HIV clinic operate from the same premises.  
   Eligibility criteria at both hospitals match the national ARV 
guidelines. HIV testing, adherence counselling and treatment 
are done on a one-to-one basis with the staff doctor to preserve 
Financial and economic costs of scaling up the provision of 
HAART to HIV-infected health care workers in KwaZulu-
Natal
N Deghaye, R A Pawinski, C Desmond
Objectives. To provide new information on the financial and 
economic costs of providing highly active antiretroviral therapy 
(HAART) to health care workers in public-sector hospital 
settings in KwaZulu-Natal.  
Design. An Excel model was used to estimate the cost of 
providing HAART to health care workers at two state-
subsidised hospitals in Durban.  Staff members were 
interviewed and protocols reviewed to identify the time and 
resources used to provide HAART to health care workers.  
The cost of the programme was estimated for various patient 
numbers.    
Results.  The financial cost of treating a patient for a year 
ranged from R5 697 to R8 762 depending on the hospital and 
the number of patients treated.  The economic cost of treating 
a patient for a year ranged from R6 123 to R8 893.  These costs 
were shown to be robust to changes in key variables.  
Conclusions. This study provides evidence on the cost of 
providing HAART to health care workers and suggests that 
this strategy could reduce absenteeism and alleviate future staff 
shortages at moderate cost to hospitals.  This is crucial, given 
the impending human resources crisis in health care in South 
Africa and the growing burden of HIV/AIDS.  These cost 
estimates should be good indicators of the costs of extending 
antiretroviral therapy to health care workers in public-sector 
hospitals in KwaZulu-Natal.
S Afr Med J 2006; 96: 140-143.
Enhancing Care Initiative, KwaZulu-Natal PLUS, Nelson R Mandela School of 
Medicine, University of KwaZulu-Natal, Durban
N Deghaye, BCom Hons (Econ), MSc (Health Econ)
R A Pawinski, MB ChB, DipObst, DTMH, DipEPI
Enhancing Care Initiative, KwaZulu-Natal PLUS, Nelson R Mandela School of 
Medicine, University of KwaZulu-Natal, Durban, and Human Sciences Research 
Council, Durban
C Desmond, MA (Econ)
Corresponding author: R A Pawinski (pawinskir@ukzn.ac.za)
pg 140-143.indd   140 1/17/06   4:19:37 PM
ORIGINAL ARTICLES
141
February 2006, Vol. 96, No. 2  SAMJ
staff confidentiality and to encourage staff to take up HIV 
treatment.  In November 2004, there were 20 and 21 staff 
members on HAART at the two hospitals respectively.
   As shown in Table I, the drug regimens prescribed differed 
slightly between the two hospitals.  Hospital A prescribed 
Combivir, which will be phased out to fall in line with national 
guidelines.  
Methods 
Financial and economic costs of HAART provision were 
estimated.  Financial costs were considered to be all additional 
costs incurred as a result of introducing this programme.  
Financial costs included the cost of buildings acquired and 
salaries of new staff hired as a result of introducing the 
programme (fixed costs) and the cost of drugs, medical 
consumables, testing and monitoring (variable costs).
   Economic costs were considered to be the total resource 
usage of the programme.  These costs included the above as 
well as the cost of hours existing staff members worked on the 
programme, and using existing buildings and equipment on 
the programme.
   These resources would have been put to alternative uses if 
they had not been deployed on the HAART programme.  As 
such, these costs should be included to reflect overall resource 
usage. 
   The costing was carried out from the perspective of the 
individual hospital.  It included all costs borne by the hospital, 
but not the additional costs that might be borne by the 
Department of Health (DOH) if this intervention were adopted 
as policy (for example provincial overheads, monitoring and 
evaluation, and training costs).  
   Key hospital staff were interviewed, face-to-face, and 
protocols reviewed to identify the activities and resources used 
(staff time, equipment, consumables and premises) and the 
frequency of consultations and laboratory testing.  
   The resources used for each activity were estimated by 
combining data on yearly patient usage, average time taken per 
activity and yearly operational hours for each resource.  Unit 
prices were then applied to each resource.  The total cost of 
HAART provision was established by adding the costs of all 
component activities.  
   The model used drug prices available to the South African 
government as at November 2004 and the Combivir access 
price as at October 2004. DOH salary information and drug 
and laboratory test prices available to provincial hospitals were 
used in the model.  
   An Excel model, developed by the Enhancing Care Initiative 
KZN PLUS and the Harvard AIDS Institute, was amended 
and was used to combine the cost data collected.  The model 
estimates the costs of the HAART programme at different 
patient numbers.  In addition, it calculates the maximum 
number of patients each resource can service in a year and 
capacity utilisation of each resource at different patient 
numbers, given assumptions about the percentage of time it is 
available to be used on this programme. 
   In modelling the programme, 70% of patients were assumed 
to be in their first year of treatment.  The proportion of staff 
on each drug regimen was based on the current proportions at 
each hospital.  
   The cost of the HAART programme was estimated for 
current patient numbers, for estimated patient numbers when 
the national prevalence rate for health care workers5 (16%) 
is applied, and for estimated patient numbers when a 20% 
prevalence rate is applied.  It was assumed that half of all HIV-
positive staff members would be on HAART at any point.  
   This model is unique as it allows researchers to determine 
the changing resource requirements of a programme as 
patient numbers increase.  The proportion of total staff time 
and facility time allocated to the programme is calculated 
for different patient numbers.  This model estimates how per 
patient cost of HAART changes with patient numbers and 
estimates at what point new investment in facilities is needed.  
This is an advantage over other models that assume a static 
cost per patient and do not allow for economies of scale.  
Human resource costs of programmes are often neglected.  This 
model focuses on human resource costs.
   At both hospitals, facilities and staff were shared with 
other programmes.  The costing approach used allowed 
the researchers to estimate the percentage of time that each 
resource was used on this programme.  This percentage was 
applied to all costs shared with other programmes (for example 
cleaning and maintenance) to estimate the proportion to be 
allocated to this programme.
Results 
The results of the model (summarised in Table II) show that, at 
current patient numbers, it costs between R5 697 and  
R8 762 to treat one health care worker with HAART for 1 year 
(costs for hospitals B and A, respectively).
   The difference in financial cost between the hospitals is 
largely explained by the higher fixed costs at Hospital A.  At 
both hospitals, the HAART programme for health care workers 
was introduced after HAART for the general public.  There 
Table I.  Proportion of patients on each regimen 
 Proportion of patients on
Regimen regimen (%)
Hospital A
   D4T, 3TC, efavirenz 65
   Combivir, efavirenz 30
   Combivir, nevirapine   5
Hospital B
   D4T, 3TC, efavirenz 90
   D4T, 3TC, nevirapine 10
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was no capital expenditure (land, buildings or equipment) 
associated with the introduction of this programme.  As 
a result, there were no fixed costs of the programme at 
Hospital B.  At Hospital A the introduction of the programme 
necessitated that staff extend their working hours.  The cost of 
additional working hours is a fixed labour cost (of R55 799 per 
year).  
   Estimates of staff capacity utilisation generated by the 
model show that even if the number of health care workers 
on HAART increases to 47, no new staff would be needed at 
either hospital if the current workload on other programmes 
remained unchanged.  
   The variable costs associated with the programme are 
strikingly similar across hospitals (R5 972 and R5 697 per 
patient per year at hospitals A and B respectively).  The cost of 
ARV drugs was the largest cost component.
   The economic cost of treating 1 patient for 1 year, at current 
patient numbers, was R8 893 at Hospital A and R 6 778 at 
Hospital B.  There was less difference in the economic cost 
between the programmes as the opportunity cost of staff time 
was included for Hospital B.  At Hospital B the introduction 
of HAART for health care workers meant that staff time 
was diverted from other activities.  The opportunity cost of 
diverting staff time was estimated at R929 per patient per year.  
Including this cost provides a more accurate estimate of the 
total cost of HAART at Hospital B.  Staff costs remained lower 
at Hospital B (R929 per patient per year) than at Hospital A 
(R2 970 per patient per year) at current patient numbers.  This 
is because less staff time was dedicated to the programme at 
Hospital B and it was not a function of differences in salaries.  
Table III shows the breakdown of economic cost in detail.         
   As patient numbers increase, the fixed costs at Hospital 
A will be spread over a larger number of patients, and the 
average cost per patient at Hospital A will decrease and 
become more similar to the cost at Hospital B (Table II).  There 
were no fixed costs at Hospital B, so average costs will not 
change as patient numbers change.       
   Hospital B provided HAART at a lower cost per patient.  
This is because less staff time was dedicated to the programme 
at Hospital B and because Hospital A was using a slightly more 
expensive drug regimen.  
   Sensitivity analysis was performed, altering several key 
variables.  As shown in Table IV, the cost estimates are robust 
to these changes.  
Discussion and conclusions 
In this study, the researchers attempted to quantify the costs of 
providing HAART to health care workers more scientifically 
than has been done previously.6  This was achieved by using 
a formal model which included the cost of human resources, 
medical consumables and equipment in 
addition to drug and testing costs. 
   As this is a model of the costs of scaling up 
treatment at facility level it cannot be used 
to estimate the cost to the provincial DOH of 
scaling up this care to all hospitals in KZN.  
Provincial costs were used in this model to 
make results generalisable to public-sector 
hospitals.  As a result this study provides a 
good estimate of what the programme might 
cost if implemented at an individual provincial 
hospital.  In introducing HAART for health 
care workers at public-sector hospitals, it is 
likely that staff time would be diverted from 
other activities (as at Hospital B).  As a result 
the cost estimates from Hospital B are likely 
Table II. Summary of results
 Hospital A Hospital B
Total financial cost per patient per year (R)
   Current patient numbers 8 762 5 697
   16% prevalence rate 7 088 5 697
   20% prevalence rate 6 858 5 697
Total economic cost per patient per year (R)
   Current patient numbers 8 893 6 778
   16% prevalence rate 7 219 6 778
   20% prevalence rate 7 114 6 778
Table IV.  Results of sensitivity analysis
  Economic cost per  
 patient per year:   
 Hospital B (R)
Baseline (21 patients)  6 778
Cost of drugs (decrease 10%) 6 450
Cost of drugs (decrease 20%) 6 123
Frequency of consultation decreased 
to match operational plan 6 348
Staff doctor salary level increased  7 003
Table III. Breakdown of economic cost per patient per year (current patient 
numbers)
  Hospital A (20 patients) Hospital B (21 patients) 
  Rands % Rands %
Fixed cost  of labour
(per patient)     2 790 31       -    0
Variable cost 
(per patient)    6 103       6 778  
   Labour (opportunity cost)       -           929 14
   Equipment and rooms 
   (opportunity cost)       131   1       152   2
   Drugs     3 660 41     3 276 48
   Tests     1 872 21     1 824 27
   Medical consumables       441   5       597   9
Total cost per patient     8 893       6 778  
Total cost (current patient 
numbers) 177 866   142 340 
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to give a more realistic indication of the cost for provincial 
hospitals.  
   There are several limitations to this study, which may impact 
on the reliability of the cost estimates.  No allowance was made 
for patients on second-line regimens.  Switching to second-
line regimens could raise per patient cost substantially.  In 
calculating the cost of labour, the researchers assumed that 
all staff time spent on HAART was additional to time spent 
on other HIV treatment.  In reality this may be offset by less 
time spent treating opportunistic infections.  Consultations 
are likely to be less frequent in hospitals that are following the 
government protocol more closely.  For both reasons the cost-
of-labour estimate here may be an overestimate.
   Time per activity was obtained from interviews with the 
clinicians implementing the programme. Where patient 
numbers are low (as is the case here), it may be difficult to 
estimate the average time for each activity accurately. The 
accuracy of cost and capacity predictions depends on the 
accuracy of these estimates and on assumptions made in the 
model.  Observation of activities could not be performed 
to validate clinicians’ estimates without compromising the 
confidentiality of HIV-positive staff members.  Experience has 
taught the authors that activity logs completed by hospital staff 
tend to be unreliable as they are often partially completed, long 
after the actual event. 
   In allocating shared costs between programmes, no account 
was taken of downtime.  As a result, the cost of the programme 
may be underestimated.  It is difficult to predict whether the 
costs of equipment and rooms at other hospitals will be similar 
to those estimated here as these depend on the infrastructure 
available at each hospital.  However, as these costs were a small 
component of total cost, this is not a significant constraint.  
   Despite these limitations, the cost estimates generated in 
this model should provide a good guideline to likely costs at 
public-sector hospitals.
   This analysis estimates the cost of introducing HAART 
for health care workers at an institution where HAART is 
already being provided to the general public and where 
the introduction of the programme requires no new capital 
expenditure.  If investment in new equipment/premises is 
required to implement the programme, this will raise the costs 
beyond those estimated here.
   For hospital managers to determine whether HAART for 
staff members makes financial sense, the costs estimated here 
should be compared with the annual costs of treating HIV-
infected health care workers without HAART (not estimated 
here).
   The costs of not providing HAART go beyond treatment 
costs.  On average, the loss of a nurse to HIV/AIDS cost two 
Johannesburg hospitals the equivalent of approximately 10 
months of nursing time, excluding treatment costs  
(D Connelly, unpublished data, 2005).  This cost includes the 
cost of death and disability benefits, recruitment and training, 
absenteeism, reduced productivity, vacancies and inexperience 
of replacement employees. 
   This study does not attempt to estimate the absenteeism 
or productivity losses of health care workers on HAART.  
However, the impact of HAART on absenteeism and worker 
productivity should be considered by hospital managers.  
Southern African research shows that formal-sector employees 
who died or left employment because of HIV/AIDS took 11 
- 68 more days’ sick leave in their final year of employment 
than others.  They were between 22% and 63% less productive 
in their final year of employment than before they took ill.7  
Providing HAART can delay the onset of AIDS and shift these 
costs into the future.  Preliminary data from Anglo American’s 
HIV/AIDS treatment programme shows that 70% of the cost 
of providing ART is covered by savings in absenteeism.8  It 
seems reasonable to expect that similar savings could be 
experienced in hospitals.  The potential impact of this strategy 
on absenteeism is particularly important given widespread 
staff shortages in health care. 
   Although the comprehensive plan for the HIV/AIDS Care 
and Treatment Plan for South Africa includes the care of 
health workers, it does not specify the extent of this care.3  
Providing HAART to health care workers could be the first 
step institutions could take to provide HAART.  The results of 
this costing study suggest that this strategy could go some way 
towards alleviating the skills crisis in health care in resource-
constrained settings at moderate cost.
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